homevideos Newshealthcare News

Indian pharma companies sold emergency use COVID 19 drugs worth Rs 2,600 crore in 12 months

videos | Sept 13, 2021 10:14 PM IST

Indian pharma companies sold emergency use COVID-19 drugs worth Rs 2,600 crore in 12 months

Mini

Favipiravir, which was dropped from the treatment guidelines earlier this year cornered 50 percent of the total sales, worth nearly Rs 1,300 crore.

In the last 12 months, Indian pharma companies have managed to sell emergency use COVID-19 drugs worth more than Rs 2,600 crore.

Recommended Articles

View All

Favipiravir, which was dropped from the treatment guidelines earlier this year cornered 50 percent of the total sales, worth nearly Rs 1,300 crore.
Ekta Batra reports that Remdesivir logged the second-highest sales at Rs 931 crore while Tocilizumab clocked sales worth Rs 175 crore.
Watch video for more details.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng